Drug Profile
CRISPR/Cas9 modified human haematopoietic stem cell therapy - Allife Medical Science and Technology
Alternative Names: Beta-globin gene therapy - Allife Medical Science and Technology; iHSCs - Allife Medical Science and Technology; Induced haematopoietic stem cells - Allife Medical Science and Technology; Patient-specific iHSC therapy - Allife Medical Science and Technology; Patient-specific induced haematopoietic stem cell therapy - Allife Medical Science and TechnologyLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Allife Medical Science and Technology
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements; Gene transference; Haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Beta-thalassaemia
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Beta-thalassaemia in Unknown (IV, Injection)
- 02 Nov 2018 Preclinical trials in Beta-thalassaemia (IV)
- 02 Nov 2018 Allife Medical Science and Technology plans an early phase I trial for Beta-thalassaemia (In children, In adolescents, In adults) (NCT03728322)